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SUMMARY
This paper discusses the evolving concept of atrial myopathy by presenting how it develops and how it affects the properties of the atria. It also reviews the complex relationships among atrial myopathy, atrial fibrillation (AF), and stroke. Finally, it discusses how to apply the concept of atrial myopathy in the clinical setting-to identify patients with atrial myopathy and to be more selective in anticoagulation in a subset of patients with AF. An apparent lack of a temporal relationship between episodes of paroxysmal AF and stroke in patients with cardiac implantable electronic devices has led investigators to search for additional factors that are responsible for AF-related strokes. Multiple animal models and human studies have revealed a close interplay of atrial myopathy, AF, and stroke via various mechanisms (e.g., aging, inflammation, oxidative stress, and stretch), which, in turn, lead to fibrosis, electrical and autonomic remodeling, and a pro-thrombotic state. The complex interplay among these mechanisms creates a vicious cycle of everworsening atrial myopathy and a higher risk of more sustained AF and strokes. By highlighting the importance of atrial myopathy and the risk of strokes independent of AF, this paper reviews the methods to identify patients with atrial myopathy and proposes a way to incorporate the concept of atrial myopathy to guide anticoagulation in providing the substrate for re-entry (14) (15) (16) (17) . Atrial interstitial fibrosis has been observed in patients with AF (18) . In dogs with heart failure induced by rapid ventricular pacing, extensive atrial fibrosis underlies the mechanism by which AF is much easier to be induced and become sustained, despite unaltered atrial electrophysiological parameters (19) . Fibroblast proliferation and extracellular matrix deposition in response to insults such as aging (20) , atrial stretch (16) , inflammation (21, 22) , and oxidative stress (21, 23) may predispose to anisotropy and re-entry (24) . The electrical derangement adds to a vicious cycle in which "AF begets AF" (25)-rapid atrial myocyte depolarization leads to intracellular calcium accumulation, triggering adaptive and inflammatory responses that potentiate myocyte apoptosis and accelerate atrial fibrosis (26).
Histologically, atrial fibrosis is characterized by cardiomyocytes exhibiting loss of sarcomeres as well as accumulation of glycogen storage granules, which are adaptive alterations in cellular metabolism not unlike those observed in response to ischemia (27) . A principal mediator of AF-induced atrial cardiomyocyte apoptosis and necrosis is calpain (28), a protein concentrated in or near the nucleus, and intercalated discs, which are capable of both proteolysis and degradation of L-type calcium channels (29) . Other potential mediators of structural remodeling include platelet-derived growth factor, atrial natriuretic peptide, and galectin-3 (30, 31) . In addition, the renin-angiotensin system appears to play a role, because angiotensin-converting enzyme inhibitors (or angiotensin-receptor blockers) blunt atrial fibrosis (32) and decrease the incidence of AF in heart failure in both animal (33, 34) and clinical studies (35, 36) . Transforming growth factor-b (TGF-b) also has an important role. Mouse models that overexpress TGF-b1 have profound atrial fibrosis and AF (with normal ventricles) (15) . In a canine model of heart failure with extensive atrial fibrosis, the drug pirfenidone significantly reduced atrial fibrotic remodeling and vulnerability, and was associated with a significant reduction in the expression of TGFb1 (37) . In a canine heart failure model, Kunamalla et al. (38) Shen et al.
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which worsens the atrial myopathic processes that then help to sustain more AF? The following sections help to further highlight the concept that although AF may lead to the initiation and/or progression of this myopathy, the presence of AF is by no means essential to the development or the maintenance of this myopathic state.
ATRIAL MYOPATHY AND THE AGING HEART
Aging leads to advancing decline in the structure and function of the heart, and is a leading risk factor for cardiovascular diseases (39) , including AF. Although Atrial myopathy is typically caused by insults such as aging, inflammation, oxidative stress, and stretching of the atria. These myopathic changes alter the properties of myocardial electrophysiology and cardiac autonomic nervous system. They can also lead to architectural structural changes characterized by Shen et al. Shen et al. 13. Kottkamp H. Fibrotic atrial cardiomyopathy: a specific disease/syndrome supplying substrates for atrial fibrillation, atrial tachycardia, sinus node
